RETROSIRGO: Sirolimus in Graves' Orbitopathy

Sponsor

University of Pisa (Other)

Overall Status

Completed

CT.gov ID

NCT05345119

Collaborator

(none)

Enrollment

Location

Actual Duration (Months)

1.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast proliferation and release of glycosaminoglycans. The current treatments available, especially glucocorticoids, are not effective in all patients. Two cases of patients with GO treated with Sirolimus have been reported with an excellent response to the drug.

The rationale for the use of Sirolimus lies in its mechanisms of action. Sirolimus is able to inhibit T-cell activation as well as fibroblast proliferation. In addition, acts indirectly on the Insulin-Like Growth Factor-1 (IGF-1) pathway, and recent clinical trials have shown that a monoclonal antibody against the IGF-1 receptor (Teprotumumab) is effective in patients with GO. Thus, Sirolimus could be used in GO as monotherapy in patients with GO.

The aim of the present drug vs standard treatment, observational study is to evaluate the efficacy of Sirolimus as a second-line treatment in patients with moderately severe, active GO.

Condition or Disease	Intervention/Treatment	Phase
Graves Ophthalmopathy	Drug: Sirolimus Drug: Methylprednisolone

Detailed Description

Study Design: observational

Thirty consecutive patients with moderate-to-severe and active GO treated with sirolimus (15 patients) or methylprednisolone (15 patients) observance 18 consecutive months will be compared.

Study Timeline

Baseline visit - (Time 0) Treatment period (week 1-week 12): daily administration of the trial agent (Sirolimus) or weekly administration of the standard treatment (methylprednisolone) Outcome visit (week 24)

Study Design

Study Type:

Observational

Actual Enrollment :

30 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)

Actual Study Start Date :

Jan 15, 2020

Actual Primary Completion Date :

Jun 15, 2021

Actual Study Completion Date :

Jun 15, 2021

Arms and Interventions

Arm	Intervention/Treatment
Sirolimus Treatment with sirolimus for 12 weeks, given as a second-line treatment	Drug: Sirolimus 2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
Methylprednisolone Treatment with methylprednisolone for 12 weeks, given as a second-line treatment	Drug: Methylprednisolone 500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).

Arm

Intervention/Treatment

Sirolimus

Treatment with sirolimus for 12 weeks, given as a second-line treatment

Drug: Sirolimus

2 mg orally on the first day followed by 0.5 mg per day for 12 weeks

Methylprednisolone

Treatment with methylprednisolone for 12 weeks, given as a second-line treatment

Drug: Methylprednisolone

500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).

Outcome Measures

Primary Outcome Measures

GO overall response [24 weeks]
Percentage of subjects with at least two of the following compared to baseline: a) Improvement in clinical activity score (CAS) by at least 1 point ; b) Improvement in exophthalmos by at least 2 mm; c) Improvement in lid aperture by at least 2 mm; d) Improvement in eye muscle ductions ≥8 degrees; e) Improvement of visual acuity by at least 0.2/1, without worsening of any of these parameters in the contralateral eye if applicable.

Secondary Outcome Measures

Change in exophthalmos [24 weeks]
Percentage of subjects with a reduction greater than or equal to 2 mm compared with the baseline evaluation in the study eye, without worsening in the contralateral eye
Change in the clinical activity score (CAS) [24 weeks]
Percentage of subjects with a reduction of CAS by at least two points in the study eye, without worsening in the contralateral eye
Change in quality of life [24 weeks]
Comparison of the quality of life scores between the two groups, determined with a questionnaire specific for GO (GO-QoL)
Change in eye ductions [24 weeks]
Percentage of subjects with an increase in eye ductions at least 8 degrees
Change in eyelid aperture [24 weeks]
Percentage of subjects with a reduction greater than or equal to 2 mm
Change in diplopia [24 weeks]
Percentage with an improvement in diplopia

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients willing and capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
A moderate-to-severe GO, defined as the presence of at least one of the following criteria: an exophthalmos ≥2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm
Active GO: CAS (4) ≥2 out of 7 points in the most affected eye
Previous GO treatment with glucocorticoids and/or orbital radiotherapy and/or orbital decompressive surgery, performed more than 24 weeks before the current treatment
Male and female patients of age: 18-75 years

Exclusion Criteria:

Optic neuropathy
Treatment with glucocorticoids or other immunosuppressive medications, and/or selenium, and/or orbital radiotherapy and/or orbital decompressive surgery in the 24 weeks preceding the current treatment
Mental illness that prevents patients from comprehensive, written informed consent